Yi-Wen Hong1, Jen-Der Lin2, Ming-Chin Yu1, Chih-Chieh Hsu1, Yann-Sheng Lin3. 1. Department of Surgery, Chang Gung Memorial Hospital Linkou Branch, Chang Gung University, No. 5, Fuxing St, Guishan Dist, Taoyuan City 333, Taiwan. 2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou Branch, Chang Gung University, No. 5, Fuxing St, Guishan Dist, Taoyuan City 333, Taiwan. 3. Department of Surgery, Chang Gung Memorial Hospital Linkou Branch, Chang Gung University, No. 5, Fuxing St, Guishan Dist, Taoyuan City 333, Taiwan. Electronic address: m7203@cgmh.org.tw.
Abstract
BACKGROUND: Cranial metastasis of thyroid cancer is rare. The aim of this study was to analyse the clinical characteristics, treatments and outcomes of thyroid cancer patients with cranial metastasis and to identify the associated prognostic factors. MATERIALS AND METHODS: Between January 1977 and August 2017, a total of 4683 patients were histologically confirmed to have thyroid cancer. Among them, 25 patients (0.53%) were identified as having cranial metastases, and their medical records were reviewed. The Kaplan-Meier method with a log-rank test was performed with cancer-specific survival as the main outcome. Cox regression analysis was used to examine the potential prognostic factors influencing patient survival. RESULTS: Of the 25 patients, 21 were female, and 4 were male. The median age at the time of diagnosis of cranial metastasis was 63 years. Sixteen patients had metastases to the brain, and nine patients had metastases involving the skull only. Papillary carcinoma and follicular carcinoma accounted for 84.0% of cases. Twenty-four cases (96.0%) had extracranial metastases at the time of diagnosis of cranial metastases. Twenty patients received surgery, and 4 patients received palliative radiotherapy. One patient received supportive care only. The median cancer-specific survival after the diagnosis of cranial metastases was 27 months. According to the Kaplan-Meier test, 3 factors had a significant impact on survival, the metastatic site, histological types and surgical resection. According to the Cox regression analysis, skull metastases (HR: 0.274, 95% CI: 0.083-0.904, p = 0.033) and surgical resection (HR: 0.134, 95% CI: 0.019-0.929, p = 0.042) were identified as independent prognostic factors for a better outcome. CONCLUSIONS: Surgical resection is the mainstay therapy for thyroid cancer patients with cranial metastasis. Cranial metastases involving the skull only are associated with a better outcome.
BACKGROUND: Cranial metastasis of thyroid cancer is rare. The aim of this study was to analyse the clinical characteristics, treatments and outcomes of thyroid cancerpatients with cranial metastasis and to identify the associated prognostic factors. MATERIALS AND METHODS: Between January 1977 and August 2017, a total of 4683 patients were histologically confirmed to have thyroid cancer. Among them, 25 patients (0.53%) were identified as having cranial metastases, and their medical records were reviewed. The Kaplan-Meier method with a log-rank test was performed with cancer-specific survival as the main outcome. Cox regression analysis was used to examine the potential prognostic factors influencing patient survival. RESULTS: Of the 25 patients, 21 were female, and 4 were male. The median age at the time of diagnosis of cranial metastasis was 63 years. Sixteen patients had metastases to the brain, and nine patients had metastases involving the skull only. Papillary carcinoma and follicular carcinoma accounted for 84.0% of cases. Twenty-four cases (96.0%) had extracranial metastases at the time of diagnosis of cranial metastases. Twenty patients received surgery, and 4 patients received palliative radiotherapy. One patient received supportive care only. The median cancer-specific survival after the diagnosis of cranial metastases was 27 months. According to the Kaplan-Meier test, 3 factors had a significant impact on survival, the metastatic site, histological types and surgical resection. According to the Cox regression analysis, skull metastases (HR: 0.274, 95% CI: 0.083-0.904, p = 0.033) and surgical resection (HR: 0.134, 95% CI: 0.019-0.929, p = 0.042) were identified as independent prognostic factors for a better outcome. CONCLUSIONS: Surgical resection is the mainstay therapy for thyroid cancerpatients with cranial metastasis. Cranial metastases involving the skull only are associated with a better outcome.
Authors: Suwardjo Suwardjo; Widya Surya Avanti; Ery Kus Dwianingsih; Wirsma Arif Harahap; Sumadi Lukman Anwar Journal: Ann Med Surg (Lond) Date: 2020-11-28
Authors: Abdulaziz Alanazi; Ali Alkhaibary; Sami Khairy; Fahd Al Sufiani; Ali H Alassiri; Ahmed Aloraidi; Ahmed Alkhani Journal: Surg Neurol Int Date: 2022-03-25
Authors: Lynda N Bile-Gui; Eric Kouadio; Estelle Valérie Ohui-Acko; Raissa M Kabas; Sylvanus B Koui; Lolo M A Diambra; Jean-Paul S Kouao Journal: Radiol Case Rep Date: 2019-11-23